STOCK TITAN

Point72 (NASDAQ: BBNX) holds 2.29M shares, a 5.2% stake in Beta Bionics

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G

Rhea-AI Filing Summary

Point72 Asset Management, Point72 Capital Advisors Inc., and Steven A. Cohen report shared beneficial ownership of 2,290,023 shares of Beta Bionics common stock, representing 5.2% as of February 20, 2026.

The filing states these Reporting Persons hold the shares through Point72 Associates, LLC, with shared voting and dispositive power of 2,290,023 shares. The cover page figures are reported as of the close of business on February 20, 2026.

Positive

  • None.

Negative

  • None.

Insights

Point72 holds a 5.2% passive stake in Beta Bionics via Point72 Associates.

Point72 Asset Management, Point72 Capital Advisors Inc., and Steven A. Cohen are listed as joint filers reporting shared voting and dispositive power over 2,290,023 shares as of February 20, 2026. The shares are held by Point72 Associates and reported under a Joint Filing Agreement.

The filing does not state any transactions, purchases, or sale intent in this excerpt; subsequent filings would disclose changes. Cash-flow treatment and trading plans are not included in the provided excerpt.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Point72 Asset Management, L.P.
Signature:/s/ Jason M. Colombo
Name/Title:Jason M. Colombo, Authorized Person
Date:02/23/2026
Point72 Capital Advisors, Inc.
Signature:/s/ Jason M. Colombo
Name/Title:Jason M. Colombo, Authorized Person
Date:02/23/2026
Steven A. Cohen
Signature:/s/ Jason M. Colombo
Name/Title:Jason M. Colombo, Authorized Person
Date:02/23/2026
Exhibit Information

Exhibit 99.1: Joint Filing Agreement

FAQ

How many Beta Bionics (BBNX) shares does Point72 report owning?

Point72 reports beneficial ownership of 2,290,023 shares. The filing shows this number as the shared voting and dispositive power held by the Reporting Persons as of February 20, 2026.

What percent of Beta Bionics does Point72 hold according to the filing?

The filing reports a 5.2% stake in Beta Bionics. That percentage corresponds to the 2,290,023 shares reported as beneficially owned as of February 20, 2026.

Through which entity does Point72 hold its Beta Bionics stake?

The shares are held through Point72 Associates, LLC, an investment fund managed by Point72 Asset Management. Point72 Capital Advisors Inc. is the general partner and Steven A. Cohen controls the reporting entities.

Does the filing show who has voting or dispositive power over the shares?

Yes. The filing shows shared voting power and shared dispositive power of 2,290,023 shares for each Reporting Person, with no sole voting or dispositive power reported.

When is the ownership information effective in the schedule 13G?

The ownership figures are reported as of the close of business on February 20, 2026. The signatures on the filing are dated February 23, 2026.
Beta Bionics, Inc.

NASDAQ:BBNX

BBNX Rankings

BBNX Latest News

BBNX Latest SEC Filings

BBNX Stock Data

610.41M
43.46M
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
IRVINE